- Scientific and clinical data on BriaCell’s (BCT) lead candidate, Bria-IMT, was recently published on-line
- The publication highlighted the approach to developing novel cellular immunotherapies for cancer and the safety and efficacy of Bria-IMT against advanced breast cancer in a prior clinical study through a potentially unique mechanism of action
- BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for cancer management
- BriCell Therapeutics (BCT) opened trading at C$7.25 a share
Scientific and clinical data on BriaCell’s (BCT) lead candidate, Bria-IMT was recently published on-line in Recent Patents on Anti-Cancer Drug Discovery.
The publication focused on research in leading therapeutic areas, targets, and agents related to anti-cancer drug discovery and highlighted the approach to developing novel cellular immunotherapies for cancer and the safety and efficacy of Bria-IMT against advanced breast cancer in a prior clinical study through a potentially unique mechanism of action.
BriaCell’s President and CEO, Dr. William V. Williams, MD, explained that the paper highlights the company’s findings of rapid tumour shrinkage in multiple anatomic locations, including difficult-to-treat sites like the brain.
“We are even more excited to see the potential positive effect on survival in these patients. Having these scientific and clinical findings published in such a highly regarded journal is a significant achievement for BriaCell. The results support our approach for selecting patients most likely to benefit from our immunotherapy. This undergirds our current strategy of building a pipeline of off-the-shelf personalized immunotherapies as potentially safe and effective treatments for advanced breast cancer and other cancers.”
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for cancer management.
BriCell Therapeutics (BCT) opened trading at C$7.25 a share.
